Nyrada (ASX:NYR) Equity-to-Asset : 0.90 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Nyrada's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$4.58 Mil. Nyrada's Total Assets for the quarter that ended in Dec. 2023 was A$5.06 Mil.

The historical rank and industry rank for Nyrada's Equity-to-Asset or its related term are showing as below:

ASX:NYR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.82 Med: 0.89 Max: 0.96
Current: 0.9

During the past 5 years, the highest Equity to Asset Ratio of Nyrada was 0.96. The lowest was 0.82. And the median was 0.89.

ASX:NYR's Equity-to-Asset is ranked better than
84.95% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs ASX:NYR: 0.90

Nyrada Equity-to-Asset Historical Data

The historical data trend for Nyrada's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Equity-to-Asset Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Equity-to-Asset

0.96

0.88

0.96

0.82

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.96	0.96	0.88	0.82	0.90

Competitive Comparison of Nyrada's Equity-to-Asset

For the Biotechnology subindustry, Nyrada's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Nyrada's Equity-to-Asset falls into.

Nyrada Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Nyrada's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	4.258	/	5.165
	=

Nyrada's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	4.578	/	5.063
	=

Nyrada (ASX:NYR) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Nyrada Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Nyrada's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines